IRIS
LODI, Tiziana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.483
AS - Asia 4.677
EU - Europa 4.244
SA - Sud America 758
AF - Africa 225
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 4
Totale 16.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.323
SG - Singapore 1.941
CN - Cina 1.655
IE - Irlanda 811
IT - Italia 687
SE - Svezia 681
BR - Brasile 615
FI - Finlandia 556
UA - Ucraina 487
DE - Germania 403
HK - Hong Kong 400
VN - Vietnam 296
NL - Olanda 185
ZA - Sudafrica 176
TR - Turchia 140
GB - Regno Unito 135
CA - Canada 115
FR - Francia 76
RU - Federazione Russa 74
AR - Argentina 49
IN - India 43
BE - Belgio 36
IQ - Iraq 33
BD - Bangladesh 31
MX - Messico 30
EC - Ecuador 29
ES - Italia 24
JP - Giappone 23
PL - Polonia 18
CO - Colombia 15
KR - Corea 15
ID - Indonesia 14
UZ - Uzbekistan 13
VE - Venezuela 12
CZ - Repubblica Ceca 11
CI - Costa d'Avorio 10
CL - Cile 10
PY - Paraguay 10
DO - Repubblica Dominicana 8
EG - Egitto 8
MA - Marocco 8
PE - Perù 8
PK - Pakistan 8
EU - Europa 7
IR - Iran 7
LT - Lituania 7
UY - Uruguay 7
AT - Austria 6
RS - Serbia 6
SA - Arabia Saudita 6
DZ - Algeria 5
KE - Kenya 5
KZ - Kazakistan 5
PH - Filippine 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
AZ - Azerbaigian 4
CH - Svizzera 4
LB - Libano 4
NO - Norvegia 4
NP - Nepal 4
RO - Romania 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
JO - Giordania 3
KG - Kirghizistan 3
MK - Macedonia 3
OM - Oman 3
TN - Tunisia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
ET - Etiopia 2
GE - Georgia 2
GY - Guiana 2
IL - Israele 2
JM - Giamaica 2
LV - Lettonia 2
NG - Nigeria 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TH - Thailandia 2
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
GT - Guatemala 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
MC - Monaco 1
MD - Moldavia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
Totale 16.393
Salva come PNG Salva come JPEG
Città #
Singapore 935
Dublin 799
Chandler 791
Ashburn 681
Santa Clara 569
Jacksonville 541
Beijing 414
Hong Kong 394
Dallas 359
Ann Arbor 282
Dearborn 282
Boardman 235
Nanjing 209
Parma 197
Johannesburg 164
Princeton 155
Los Angeles 151
San Mateo 132
Izmir 123
Wilmington 118
Ho Chi Minh City 113
Shanghai 109
New York 107
Toronto 88
Jinan 75
Shenyang 71
Hanoi 65
Hefei 61
Nanchang 61
São Paulo 60
Helsinki 58
Des Moines 54
Moscow 53
Kunming 52
Munich 51
Woodbridge 50
Hebei 48
Buffalo 43
Guangzhou 37
Brussels 34
Tianjin 32
Falls Church 30
Jiaxing 30
Columbus 27
Changsha 26
Dosolo 26
Houston 26
Seattle 25
Brooklyn 21
The Dalles 21
Phoenix 20
Rio de Janeiro 20
Zhengzhou 20
Council Bluffs 19
Redmond 18
Tokyo 18
Padova 17
Bremen 16
Haikou 16
London 16
Warsaw 16
Baghdad 15
Amsterdam 14
Bologna 14
Fremont 14
Fuzhou 14
Hangzhou 14
Marseille 14
Atlanta 13
Belo Horizonte 13
Taizhou 13
Catania 12
Chennai 12
Da Nang 12
Denver 12
Orem 12
Rome 12
San Francisco 12
Seoul 12
Milan 11
Modena 11
Norwalk 11
Redwood City 11
Turku 11
Abidjan 10
Auburn Hills 10
Brasília 10
Frankfurt am Main 10
Lanzhou 10
Mexico City 10
Quito 10
Rockville 10
Stockholm 10
Tashkent 10
Boston 9
Chicago 9
Curitiba 9
Guarulhos 9
Guayaquil 9
Haiphong 9
Totale 9.724
Salva come PNG Salva come JPEG
Nome #
Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study 289
Yeast, worm, patient’s fibroblasts and zebrafish as models for drug repositioning of molecules targeting POLG-related diseases 178
A yeast-based repurposing approach revealed modulation of dNTP pool as a therapeutic target to treat mitochondrial DNA depletion syndromes 178
DNA polymerase [gamma] and disease: what we have learned from yeast 176
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 173
A chemical genomic approach to characterize the antiproliferative activity of metal based drugsdriven by phenotypic screening in yeast as a model organism 170
A chemical genomic approach to characterize the antiproliferative activity of metal-based drugs driven by phenotipic screening in yeast as a model organism 160
Sabotage at the powerhouse? Unraveling the Molecular Target of 2-Isopropylbenzaldehyde Thiosemicarbazone, a Specific Inhibitor of Aflatoxin Biosynthesis and Sclerotia Development in Aspergillus flavus, Using Yeast as a Model System 157
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island 157
Amino and carboxy-terminal extensions of yeast mitochondrial DNA polymerase assemble both the polymerization and exonuclease active sites 152
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 151
Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy 150
A Klaac null mutant of Kluyveromyces lactis is complemented by a single copy of the Saccharomyces cerevisiae AAC1 gene 150
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models 149
Screening of thiosemicarbazones as antimycotic drugs 146
Characterization of a promoter mutation in the CYP3 gene of S. cerevisiae which cancels regulation by Cyp1p (Hap1p) without affecting its binding site 145
IMP2, a nuclear gene controlling the mitochondrial dependence of galactose, maltose and raffinose utilization in Saccharomyces cerevisiae. 145
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 145
A single nucleotide polymorphism in the DNA polymerase gamma gene of Saccharomyces cerevisiae laboratory strains is responsible for increased mitochondrial DNA mutability 143
Yeast as a model of mitochondrial dysfunctions: neurodegenerative diseases and cancer. 142
In vitro evaluation of the activity of thiosemicarbazone derivatives against mycotoxigenic fungi affecting cereals 142
S. cerevisiae carrying a MGM1/OPA1 chimeric gene: a model for the study of dominant optic atrophy and for drug discovery 140
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 137
The identification of beneficial molecules for mitochondrial diseases: Saccharomyces cerevisiae as powerful model 137
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations 137
Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive externalophthalmoplegia in humans 136
Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of Clofilium tosylate as a potential therapeutic chemical against POLG-related diseases 136
Dominance of yeast aac2R96H and aac2R252G mutations, equivalent to pathological mutations in ant1, is due to gain of function 134
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of DNA polymerase gamma allelic variants 133
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 133
A yeast-based repurposing approach for the treatment of mitochondrial DNA depletion syndromes led to the identification of molecules able to modulate the dNTP pool 133
The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases 132
Behaviour of Saccharomyces cerevisiae wine strains during adaptation to unfavourable conditions of fermentation on synthetic medium: Cell lipid composition, membrane integrity, viability and fermentative activity 129
Allelism of IMP1 and GAL2 genes of Saccharomyces cerevisiae 129
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 128
A yeast-based screening unravels potential therapeutic molecules for mitochondrial diseases associated with dominant ant1 mutations 128
Chiral Aminoacid Containing Acyclic Ligands. I. Syntheses and Conformations 126
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of Polg allelic variants 125
A variable neurodegenerative phenotype with polymerase gamma mutation 124
Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast 124
Carbon catabolite repression in Kluyveromyces lactis: isolation and characterization of the KlDLD gene encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase. 124
Investigation of mupirocin susceptibility in bifidobacteria: physiological and genetic insights. 124
Catabolite repression by galactose in overexpressed GAL4 strains of Saccharomyces cerevisiae 122
Secretion of human serum albumin from Kluyveromyces lactis over-expressing KlPDI1 and KlERO1 genes 121
Cloning and characterization of the lactate-specific inducible gene KlCYB2, encoding the cytochrome b2 of Kluyveromyces lactis 121
Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein 121
Construction of a yeast model system for studying in vivo susceptibility to stavudine of Polg allelic variants 121
Antimycin- and hydroxamate-insensitive respiration in yeast 119
Klaac null mutant in K. lactis is complemented by a single copy of S. cerevisiae “silent” gene AAC1 119
Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae 119
Modeling of pathogenic variants of mitochondrial DNA polymerase: insight into the replication defects and implication for human disease 119
A mitochondrial role in pseudohyphal constitutive mutants obtained from a natural Saccharomyces cerevisiae strain 117
Saccharomyces cerevisiae as a system to discover beneficial molecules for mitochondrial diseases 116
Yeast expression of mammalian Onzin and fungal FCR1 suggests ancestral functions of PLAC8 proteins in mitochondrial metabolism and DNA repair 115
DEFECTIVE MITOCHONDRIAL rRNA METHYLTRANSFERASE (MRM2) CAUSES A MELAS-LIKE SYNDROME 114
LYS2 gene and its mutation in Kluyveromyces lactis 113
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in MATa/Mata diploids of Saccharomyces cerevisiae. 113
Carboxylic acids permeases in yeast: two genes in Kluyveromyces lactis.” 113
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 112
Characterization of KlGUT2, a gene of the glycerol-3-phosphate shuttle, in Kluyveromyces lactis 112
The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. 112
Identification of drugs for the treatment of POLG-related diseases by means of a high throughput drug repurposing approach performed in Saccharomyces cerevisiae 111
“Expression and structural characterization of a recombinant mouse major urinary protein” 109
Overexpression of DNA polymerase zeta and Rev1 reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 109
Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish 109
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 108
Structural modification of cuminaldehyde thiosemicarbazone increases inhibition specificity toward aflatoxin biosynthesis and sclerotia development in Aspergillus flavus 108
Overexpression of DNA polymerase zeta reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 108
“Espressione e secrezione di una Major Urinary Protein di topo nel lievito metilotrofo Pichia pastoris” 107
Elementi regolativi implicati nel processo di repressione /derepressione da glucosio in Kluyveromyces lactis: differenze rispetto a Saccharomyces cerevisiae 105
Construction and characterization of centromeric, episomal and GFP-containing vectors for Saccharomyces cerevisiae prototrophic strains 104
Comparative Functional Genomics of glucose repression in laboratory and wine yeasts 104
Saccharomyces cerevisiae, a model system to study the effect of mtDNA polymerase mutations associated with PEO in humans. 104
MIG1-dependent and MIG1-independent regulation of GAL gene expression in Saccharomyces cerevisiae: role of IMP2p 102
Klaac null mutant in K.lactis is complemented by a single copy of S.cerevisiae gene AAC1 101
L'aumento del dosaggio del gene ero1 favorisce la secrezione di proteine ricombinanti in Kluyveromyces lactis 101
Effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisiae 100
“Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein” 98
Mitmed: a multicenter consortium for the identification and characterization of nuclear genes responsisble for human mitochondrial disorders 97
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 97
“MAJOR URINARY PROTEINS: STUDIES ON THE BINDING OF FLUORESCENT MOLECULES AND ITS 13C AND 15N ENRICHED EXPRESSION IN PICHIA PASTORIS” 96
Effect of erythromycin upon proteins pattern of heat shocked S. cerevisiae. Identification of new classes of heat-shock and heat-stroke products 96
FOG1 and FOG2 genes, required for the transcriptional activation of glucose-repressible genes of Kluyveromyces lactis are homologous to GAL83 and SNF1 of Saccharomyces cerevisiae 96
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in Mata/Mata diploids of S. cerevisiae 95
Studio degli effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisae 95
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model 95
The power of yeast in modeling human mutations leading to mitochondrial disease 95
Studio del sistema ADP/ATP carrier in Kluyveromyces lactis: effetti fenotipici della distruzione del gene KlAAC e della introduzione del gene ScAAC1 nel mutante derivato. 94
Klaac null mutant in Kluyveromycs lactis is complemented by a single copy of Saccharomyces cerevisiae gene AAC1 94
Il lievito come modello per lo studio di patologie mitocondriali umane 93
Construction and validation of a yeast model system for studying in vivo the susceptibility to nucleoside analogues of DNA polymerase gamma allelic variants. 93
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 92
Oxygen is required to restore flor strain viability and lipid biosynthesis under fermentative conditions 92
Yeast as a model for drug discovery: Identification of a molecule acting as potential therapeutics for POLG-related diseases 92
Identificazione dei bersagli della proteina Imp2p in Saccharomyces cerevisiae 91
Regolazione del gene JEN1, codificante la lattato permeasi, nel lievito Saccharomyces cerevisiae 91
Galactose transport in Kluyveromyces lactis: a genomic approach 91
Three target genes for the transcriptional activator Cat8p of Kluyveromyces lactis: acetyl coenzyme A synthetase genes KlACS1 and KlACS2 and lactate permease gene KlJEN1 90
Rescue by Pol zeta overexpression of mitochondrial DNA instability due to mutations in Pol gamma in S. cerevisiae 89
Yeast model for drug discovery: Identification of molecules acting as potential therapeutics for POLG-related diseases 89
Totale 12.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.998
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021709 0 0 0 0 0 40 138 45 229 41 172 44
2021/2022787 22 16 15 36 25 24 103 120 34 67 50 275
2022/20232.873 312 276 217 220 232 329 28 193 934 18 87 27
2023/20241.028 54 86 33 30 89 241 85 112 15 88 80 115
2024/20253.286 36 176 191 224 385 505 103 132 398 280 237 619
2025/20263.762 581 668 723 644 974 172 0 0 0 0 0 0
Totale 16.634